Compare Davita Inc (DVA) vs Omnicom Group Inc. (OMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Omnicom Group Inc. — how do they compare? Davita Inc trades at $175.04 (market cap $11.28B), while Omnicom Group Inc. trades at $76.35 (market cap $20.54B). The key difference: Omnicom Group Inc. is the larger of the two by market cap, and Omnicom Group Inc. pays a 4.27% dividend while Davita Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 113 Days and Omnicom Group Inc. for 63 Days on average.
| DVA | OMC | |
|---|---|---|
Market Cap | $11.28B | $20.54B |
Volume | 650,294 | 1,803,209 |
Sector | Health | Media |
52-Week High | $240.96 | $88.94 |
52-Week Low | $103.87 | $67.27 |
Typical Hold Time | 113 Days | 63 Days |
Enterprise Value | $24.00B | $28.62B |
Dividend Yield | — | 4.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $177.02, down 1.87% on the day, showing mixed technical signals with a bearish moving average trend but neutral oscillators. Fundamentally, the company demonstrates strong earnings beats with Q2 2026 EPS of $4.02 exceeding expectations of $3.88, while revenue growth continues from $13.64B in 2025 to projected $14.0B in 2026. Recent developments include expanding value-based care partnerships with Humana, potentially benefiting over 10,000 Medicare Advantage members.
The outlook remains cautiously optimistic with 43% analyst buy ratings and a $235.67 consensus price target suggesting 33% upside. However, rising debt-to-asset ratios (65.55% in 2025) and margin pressures from Q2 2026 create headwinds. Key risks include regulatory changes in healthcare reimbursement and competitive pressures in dialysis services.
OMC trades at $76.45, up 1.8% on the day, with a bearish technical signal and mixed earnings history. The company reported a net loss of $54.5 million in 2025 despite revenue growth to $17.27 billion, though 2026 projections show a return to profitability. Recent news highlights leadership in digital marketing and significant new business wins, including $3.3 billion in H1 2026 billings.
The stock presents a value opportunity with a low P/S of 0.84 and a consensus price target of $104.67, implying 37% upside. However, high P/E of 202.35, recent net loss, and advertising market volatility pose risks. Analyst sentiment is cautious with 59% hold ratings, reflecting balanced near-term prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Omnicom Group Inc.
Omnicom is the world's second- largest ad holding company, based on annual revenue. The firm's services, which include traditional and digital advertising and public relations, are provided worldwide, with over 85% of its revenue coming from more developed regions such as North America and Europe.
Read more on OMC →
